# Symptoms and stages of ovarian cancer
Ovarian cancer typically develops in stages. However, the progression varies greatly from person to person, depending on the type of cancer, the genetic characteristics of the tumor cells, and how well the cancer responds to treatment. This page describes the most common stages of the disease progression, the associated symptoms, and what this means for daily life.
Early stage (stage I–II)
In the early stages, the cancer is still limited to the ovaries or has only recently spread to nearby tissues. These may include, for example, the peritoneum or lower abdominal organs.
**Symptoms:**
- Often few or no clear symptoms — much early ovarian cancer is discovered by chance
- Abdominal or pelvic pain (often fluctuating and mild)
- Abdominal swelling
- Change in menstrual pattern (irregularity, heavier bleeding)
- Vague sense of feeling unwell or fatigue
- Changes in digestion (nausea, constipation, altered appetite)
**Impact on daily life:**
For many women with early-stage ovarian cancer, these symptoms are subtle enough that they go unnoticed for a long time or are attributed to other causes. This is also why much ovarian cancer is detected relatively late. When symptoms are present, they may only slightly limit daily functioning.
**Details about this phase: **
The exact percentage of women in whom ovarian cancer is detected at stage I or II varies; in many Western countries, approximately 15–20% of all cases are identified at this early stage. This depends on population groups, screening programs, and access to care. Women with early-stage ovarian cancer generally have better survival chances than those with advanced disease, but precise figures vary greatly depending on tumor type and treatment.
Advanced stage (stage III–IV)
This is the most common stage at diagnosis. The cancer has spread beyond the ovaries — to the peritoneum, lymph nodes, other abdominal organs, or even further to, for example, the lungs or liver.
**Symptoms:**
- **Abdominal pain and tension:** often clearly present, sometimes severe
- **Abdominal swelling (ascites):** fluid accumulation in the abdomen, causing the abdomen to become larger and feel superficially tight and swollen
- **Changes in digestion:** nausea, vomiting, constipation, sometimes alternating with diarrhea
- **Noticeable weight loss** despite normal eating, or conversely weight gain due to fluid accumulation
- **Fatigue:** can be very pronounced and limit many activities
- **Reduced appetite:** feels full quickly
- **Changes in urination:** more frequent or burning
- **Vague general symptoms:** feeling unwell, fever (not always present)
**Impact on daily life:**
The symptoms at this stage typically have considerable impact. A swelling abdomen can change how clothes fit and cause discomfort. Nausea and fatigue can interfere with work, hobbies, and social contact. For many women, self-care (showering, dressing) becomes more strenuous. Fluid accumulation can cause breathing difficulties, especially when lying down.
**Details about this phase: **
Approximately 75–80% of all ovarian cancer diagnoses are made at stage III or IV. For high-grade serous ovarian cancer — the most common type — the median progression-free survival (time until recurrence or progression of cancer after first-line treatment) is approximately 18–24 months in recent treatment series (sources from 2024–2025). Overall five-year survival for all stages combined is around 40–50% in Western countries, but this varies considerably: early stage has better figures, advanced stage has lower figures. These numbers are averages across large groups; individual outcomes depend on many factors, including tumor type, genetic mutations (such as BRCA1/2), age, and how well the cancer responds to treatment.
Recurrence (recidive)
After first-line treatment (surgery and chemotherapy), cancer returns in many women. This can happen months or years after the initial treatment.
**Platinum-sensitive recurrence (relapse after ≥6 months treatment break):**
This occurs when cancer returns at least six months after platinum-based chemotherapy is completed.
- **Symptoms:** similar to advanced stage — abdominal pain, fluid accumulation, nausea, fatigue
- **Outlook:** these women typically have more options for retreatment, because their tumor remains sensitive to platinum chemotherapy and possibly to other medicines (PARP inhibitors)
**Platinum-resistant recurrence (relapse within <6 months):**
This occurs when cancer returns while the woman is still receiving platinum chemotherapy, or less than six months after it ends.
- **Symptoms:** can be severe and occur more quickly
- **Outlook:** this tumor is less sensitive to platinum chemotherapy; other treatments (such as bevacizumab, PARP inhibitors, or targeted medicines) are usually considered
**Impact on daily life:**
Recurrence brings hospital visits again, retreatment, and a return of side effects. For many women this feels emotionally heavy; some feel relieved that treatment is available, others experience more fatigue or fear. Daily life can be more fully taken up by medical appointments.
**Details about this phase: **
For women with platinum-sensitive recurrence, the median progression-free survival with retreatment (usually chemotherapy + PARP inhibitor or chemotherapy alone) is approximately 9–12 months, depending on which medicines are used (studies 2023–2025). For platinum-resistant recurrence this is shorter, usually 3–6 months. These are averages; some women have longer response, others shorter. PARP inhibitors (such as olaparib) used as maintenance therapy after platinum-sensitive recurrence have demonstrated in recent studies (2024–2025) that they can extend progression-free survival. Overall survival figures differ by patient group and treatment line.
Long-term response and maintenance therapy
Some women achieve long-term remission (no visible cancer on imaging) after first-line or retreatment. In this case, maintenance therapy is sometimes given — medicines to delay recurrence as long as possible.
**Symptoms:**
- In remission, symptoms of active cancer are absent
- Side effects from maintenance medication may be present (see below)
**Common maintenance medicines:**
- **PARP inhibitors** (for example olaparib, niraparib): targeting DNA repair pathways in cancer cells; can cause fatigue, anemia, nausea and vomiting
- **Bevacizumab** (anti-angiogenesis medicine): can cause blood pressure elevation, protein in urine, and affect wound healing
- **Chemotherapy**: in some cases additional chemotherapy is given
**Impact on daily life:**
Women in remission can feel largely normal. Regular monitoring (blood tests, ultrasounds, doctor visits) remains necessary. For some, fear of recurrence brings psychological burden. Side effects from maintenance medication can be chronic but are usually milder than those of intensive chemotherapy.
**Details about this phase: **
For women with a BRCA mutation (inherited genetic change) or homologous recombination deficiency, the use of PARP inhibitors as maintenance therapy is standard. In more recent studies (2024–2025) it has been demonstrated that PARP inhibitor maintenance therapy after first-line chemotherapy can extend progression-free survival by 6–12 months. Long-term effects (including risks of secondary malignancies) are still being investigated. Women without a BRCA mutation may also benefit from PARP inhibitors, depending on other genetic characteristics of their tumor.
Advanced/metastatic disease and palliative phase
If the cancer no longer responds to standard treatments, or if this is no longer meaningful, the focus shifts to symptom management and quality of life.
**Symptoms:**
- All symptoms of advanced disease may be present: severe abdominal pain, significant abdominal swelling, nausea/vomiting, fatigue, weight loss
- Breathing problems (due to fluid accumulation or lung involvement)
- Pain (in the abdomen, pelvis, sometimes elsewhere)
- Possible neuropsychiatric symptoms (confusion, drowsiness) in very late stages
**Impact on daily life:**
In this phase, self-care and comfort are central. Many women are no longer mobile without assistance. Pain management, fluid drainage (for abdominal swelling), antiemetic medication (against vomiting) and psychological support are important. Communication with your GP, home care and home team becomes more intense.
**Details about this phase: **
Median overall survival for women with advanced ovarian cancer (stage III–IV at diagnosis) is around 3–5 years, depending on tumour and treatment characteristics; however, this is an average, and individual differences are large. For platinum-resistant disease, the prognosis is shorter. These figures come from patient registries from 2020–2024. A prognosis for one person cannot be derived from these averages; only a clinician who knows the patient's specific tumour, treatment and health can provide insight into this.
When to contact your doctor
Call your clinician or visit emergency care if you experience any of the following:
- **Sudden severe abdominal pain** or abdominal tension that does not go away
- **Persistent vomiting** that prevents you from eating or drinking, and you feel dehydrated
- **Severe nausea** that prevents daily activities
- **Dizziness, fainting or very low energy level** that is new
- **Fever** (above 38.5°C), especially if you are receiving chemotherapy
- **Bleeding** (rectal, vaginal, in urine) that is abnormal
- **Severe shortness of breath** or chest pain
- **Confusion, extreme drowsiness or unusual symptoms** that develop rapidly
- **Medication side effects** that you can no longer cope with, or questions about medications
Regular contact with your team is important to catch problems early and ensure that treatment and support remain aligned.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._